With Key US Patent Upheld, Benitec Sets Sights on 'Relaunch,' $8.4M Financing
April 14, 2011
With Key US Patent Upheld, Benitec Sets Sights on 'Relaunch,' $8.4M Financing
Benitec said the funding will largely be used to advance its three preclinical drug-development programs, at least one of which is expected to enter human testing within two years.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Benitec Raises $8.5M in Oversubscribed Rights Issue
May 19, 2011 / Gene Silencing News - Genable Receives FDA Orphan Drug Status for Ocular Disease Drug
April 18, 2013 / Gene Silencing News - UC, San Diego Selected as Site for Benitec HCV Drug Trial
April 18, 2013 / Gene Silencing News - Benitec Announces Positive Animal Data with Lung Cancer Drug Candidate
April 11, 2013 / Gene Silencing News - Patents Held by Benitec, Collaborator Allowed in US, South Korea, China
April 4, 2013 / Gene Silencing News